Michael L. Meyers - 02 Feb 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Reporting relationship: SVP, Chief Medical Officer
Issuer ticker: SNDX
Reported as of: 02 Feb 2022
Net transaction value: +$295,193
SEC form: 4
Accepted by SEC: 03 Feb 2022, 16:31:53 UTC
Prior SEC filing: 03 Jan 2022
Next SEC filing: 06 Oct 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael A. Metzger, Attorney-in-Fact

Key filing fact

Michael L. Meyers filed Form 4 for Syndax Pharmaceuticals Inc (SNDX) on 03 Feb 2022.

Key facts

This page summarizes Michael L. Meyers's Form 4 filing for Syndax Pharmaceuticals Inc (SNDX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Feb 2022, 16:31.

Change

Previous filing in this sequence was filed on 03 Jan 2022.
Current net transaction value: +$295,193.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNDX transaction

Common Stock

Other

Transaction value: $21,236
Shares: +1,714
Change %: +7.9%
Price: $12.39
Shares after: 23,280
Date: 31 Jan 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNDX transaction Derivative

Stock Options (Right to buy)

Award

Transaction value: $273,956
Shares: +17,350
Change %
Price: $15.79
Shares after: 17,350
Date: 02 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 17,350
Exercise price: $15.79
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,715 shares by the Reporting Person on 1/31/22 pursuant to the Issuer's Employee Stock Purchase Plan.

Footnote F2

1/23rd of the shares subject to the option shall vest monthly over a two-year period.